0001610717-23-000406.txt : 20231219
0001610717-23-000406.hdr.sgml : 20231219
20231219173712
ACCESSION NUMBER: 0001610717-23-000406
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231215
FILED AS OF DATE: 20231219
DATE AS OF CHANGE: 20231219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Throne Jason
CENTRAL INDEX KEY: 0001790865
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38915
FILM NUMBER: 231498678
MAIL ADDRESS:
STREET 1: C/O IDEAYA BIOSCIENCES, INC.
STREET 2: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDEAYA Biosciences, Inc.
CENTRAL INDEX KEY: 0001676725
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 474268251
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-443-6209
MAIL ADDRESS:
STREET 1: 7000 SHORELINE COURT, SUITE 350
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Ideaya Biosciences, Inc.
DATE OF NAME CHANGE: 20160609
4
1
form4.xml
X0508
4
2023-12-15
0001676725
IDEAYA Biosciences, Inc.
IDYA
0001790865
Throne Jason
C/O IDEAYA BIOSCIENCES, INC.
7000 SHORELINE COURT, SUITE 350
SOUTH SAN FRANCISCO
CA
94080
true
Chief Legal Officer
true
Common Stock
2023-12-15
4
M
0
10000
13.34
A
10000
D
Common Stock
2023-12-15
4
S
0
10000
35.0371
D
0
D
Common Stock
2023-12-18
4
M
0
10000
7.01
A
10000
D
Stock Option (Right to Buy)
13.34
2023-12-15
4
M
0
10000
0
D
2030-06-30
Common Stock
10000
47610
D
Stock Option (Right to Buy)
7.01
2023-12-18
4
M
0
10000
0
D
2029-10-08
Common Stock
10000
48420
D
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 29, 2023.
This transaction was executed in multiple trades in prices ranging from $35.00 to $35.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
25% of the shares subject to the option vest on the first anniversary measured from July 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
The shares subject to the option are fully vested and exercisable.
/s/ Jason Throne
2023-12-19